Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Pfizer cans twice-daily oral obesity program
Months after making twice-daily danuglipron its top prospect, Pfizer has dropped the program after 50%+ of patients dropped out of a midphase trial.
Nick Paul Taylor
Dec 1, 2023 8:30am
Sponsored
Ethics, Regulations, and Operations of Pediatric CGT Trials
Nov 27, 2023 8:00am
After Merck's cough drama, GSK knew what to do with Bellus asset
Nov 30, 2023 8:00am
FDA recommends avoiding plastic syringes made in China
Dec 1, 2023 11:47am
Concentra back with another buyout offer, this time for LianBio
Dec 1, 2023 11:03am
Cleveland Clinic, Canon collab on imaging research center
Dec 1, 2023 10:12am
CRO News
Merck turns to Acclinate to boost diversity of cancer trials
Nov 30, 2023 8:58am
QuantHealth debuts AI-based program to simulate trials at scale
Nov 29, 2023 10:31pm
RetinAI Medical joins non-profit macular degeneration initiative
Nov 29, 2023 11:36am
BioVie blames trial sites for phase 3 Alzheimer’s drug fail
Nov 29, 2023 10:05am
See More CRO News
